Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 143Carcinoma, Neuroendocrine 56Thyroid Cancer, Papillary 54Pheochromocytoma 50Thyroid Neoplasms 41Paraganglioma 41Pituitary Neoplasms 37Adrenocortical Carcinoma 31Neoplasms 30Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 23Small Cell Lung Carcinoma 21Lung Neoplasms 21Carcinoid Tumor 20Sarcoma 19Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Prostatic Neoplasms 15Pancreatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Colorectal Neoplasms 15Carcinoma, Renal Cell 15Adrenal Gland Neoplasms 15Adenocarcinoma, Follicular 15

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Giant Cell Tumor of Bone × Endocrine × 1 year × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡